Related Experiment Video

Updated: Dec 19, 2025

Targeting Alpha Synuclein Aggregates in Cutaneous Peripheral Nerve Fibers by Free-floating Immunofluorescence Assay
08:33

Targeting Alpha Synuclein Aggregates in Cutaneous Peripheral Nerve Fibers by Free-floating Immunofluorescence Assay

Published on: June 25, 2019

8.5K

Reply to: What is the pattern of the neuropathy associated with anti-FGFR3 antibodies?

B Roy1, S Kovvuru2, Y C Castillo1

  • 1Department of Neurology, Yale University School of Medicine, New Haven, CT, USA.

European Journal of Neurology
|June 6, 2020
PubMed
Abstract

No abstract available in PubMed .

More Related Videos

Antibody Transfection into Neurons as a Tool to Study Disease Pathogenesis
06:56

Antibody Transfection into Neurons as a Tool to Study Disease Pathogenesis

Published on: September 26, 2012

11.0K
Anti-Nuclear Antibody Screening Using HEp-2 Cells
13:01

Anti-Nuclear Antibody Screening Using HEp-2 Cells

Published on: June 23, 2014

136.8K

Related Experiment Videos

Last Updated: Dec 19, 2025

Targeting Alpha Synuclein Aggregates in Cutaneous Peripheral Nerve Fibers by Free-floating Immunofluorescence Assay
08:33

Targeting Alpha Synuclein Aggregates in Cutaneous Peripheral Nerve Fibers by Free-floating Immunofluorescence Assay

Published on: June 25, 2019

8.5K
Antibody Transfection into Neurons as a Tool to Study Disease Pathogenesis
06:56

Antibody Transfection into Neurons as a Tool to Study Disease Pathogenesis

Published on: September 26, 2012

11.0K
Anti-Nuclear Antibody Screening Using HEp-2 Cells
13:01

Anti-Nuclear Antibody Screening Using HEp-2 Cells

Published on: June 23, 2014

136.8K

Related Concept Videos

Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation01:21

Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation

249
Clinical manifestationsPeripheral Arterial Disease (PAD) manifests through a range of symptoms, from the characteristic intermittent claudication to atypical presentations and severe complications in advanced stages. Intermittent claudication, a hallmark symptom of PAD, presents as exercise-induced muscle pain that typically resolves within minutes of rest. This pain is reproducible and stems from inadequate blood flow, leading to the accumulation of lactic acid produced during anaerobic...
249

Articles linked to this work by shared authors, journal, and citation graph.

Fever of unknown origin and splenomegaly in an immunosuppressed Swiss patient: case report of a Neoehrlichia mikurensis infection in a changing climate and review of the literature.

Access microbiology·2026

Addressing the Global Disparities in Access to Treatment in Spinal Muscular Atrophy.

Muscle & nerve·2026

Comparison of the Efficacy and Safety of Myasthenia Gravis Treatments: A Bayesian Network Meta-Analysis.

Neurology·2026

Pathogenic properties of myasthenia gravis AChR autoantibodies associate with clinical response to efgartigimod.

Journal of neurology, neurosurgery, and psychiatry·2026

Failure of early B cell tolerance and possible BCR signaling dysregulation underlie NF155-mediated autoimmune nodopathies.

Proceedings of the National Academy of Sciences of the United States of America·2026

A Distinct Immunological Signature in Late-Onset Myasthenia Gravis: Insights from an Exploratory Proteomics Study.

Annals of neurology·2025

Altered Saccades, Blink and Pupil Responses in Functional Motor Disorder: New Insight Into Neurobiological Mechanisms.

European journal of neurology·2026

Migraine in Older Adults: Age-Related Clinical Features From the Italian RICe Registry.

European journal of neurology·2026

Non-Invasive Intracranial Pressure Waveform Assessment as a Screening Test for Abnormal Lumbar Puncture Results.

European journal of neurology·2026

Science Is a Lot of Fun: How Professor Jes Olesen Made Discoveries in Migraine.

European journal of neurology·2026

Blood Glial Fibrillary Acidic Protein in MRI-Negative Attack-Like Episodes of Neuromyelitis Optica Spectrum Disorder.

European journal of neurology·2026

Anti-CD20 Drugs and Natalizumab Confer Equal Protection Against Progression Independent of Relapse Activity (PIRA) in People With Multiple Sclerosis.

European journal of neurology·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us